We are live on
!
Find out more
ITP
Iron Triangle Partners Portfolio holdings
AUM
$875M
1-Year Est. Return
49.85%
This Fund
S&P 500
This Quarter
Est. Return
+6.33%
1 Year Est. Return
+49.85%
3 Year Est. Return
+151.9%
5 Year Est. Return
+239.84%
10 Year Est. Return
–
AUM
$693M
AUM Growth
+$135M
(+24%)
Cap. Flow
+$108M
Cap. Flow
% of AUM
15.61%
Top 10 Holdings %
Top 10 Hldgs %
57.68%
Holding
38
New
12
Increased
10
Reduced
5
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$48.9M |
| 2 |
UnitedHealth
UNH
|
+$38.6M |
| 3 |
Evolent Health
EVH
|
+$31.6M |
| 4 |
Sanofi
SNY
|
+$25.8M |
| 5 |
DexCom
DXCM
|
+$24.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Universal Health Services
UHS
|
+$42.3M |
| 2 |
Repligen
RGEN
|
+$30.1M |
| 3 |
Boston Scientific
BSX
|
+$27.8M |
| 4 |
United Therapeutics
UTHR
|
+$19.9M |
| 5 |
Cigna
CI
|
+$19.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Sanofi
SNY
$105B
| $64.2M | 9.26% |
1,179,736
+529,736
| +81% | +$25.8M |
|
|
2
AbbVie
ABBV
$454B
| $51M | 7.36% |
+320,000
| New | +$48.9M |
|
3
Icon
ICLR
$13B
| $40.6M | 5.85% |
190,000
-35,000
| -16% | -$7.79M |
|
|
4
DexCom
DXCM
$28.3B
| $39.5M | 5.7% |
340,000
+219,920
| +183% | +$24.6M |
|
|
5
UnitedHealth
UNH
$379B
| $37.8M | 5.45% |
+80,000
| New | +$38.6M |
|
6
Acadia Healthcare
ACHC
$2.99B
| $37M | 5.34% |
512,706
+312,706
| +156% | +$24.4M |
|
7
Gilead Sciences
GILD
$162B
| $34.8M | 5.03% |
420,000
+46,431
| +12% | +$3.85M |
|
|
8
Evolent Health
EVH
$429M
| $32.5M | 4.68% |
+1,000,402
| New | +$31.6M |
|
9
Cooper Companies
COO
$13.7B
| $31.7M | 4.58% |
340,000
-152,000
| -31% | -$13.1M |
|
10
Intuitive Surgical
ISRG
$128B
| $30.7M | 4.42% |
120,000
+50,000
| +71% | +$12.3M |
|
11
Establishment Labs
ESTA
$2.71B
| $28.8M | 4.15% |
425,000
+17,926
| +4% | +$1.23M |
|
12
Surgery Partners
SGRY
$1.98B
| $28.1M | 4.06% |
815,552
-464,448
| -36% | -$15.1M |
|
13
Pacific Biosciences
PACB
$422M
| $26.6M | 3.84% |
2,300,000
+600,000
| +35% | +$5.97M |
|
14
Charles River Laboratories
CRL
$10.8B
| $26.2M | 3.78% |
130,000
-70,000
| -35% | -$15.9M |
|
15
Idexx Laboratories
IDXX
$43.9B
| $25M | 3.61% |
+50,000
| New | +$23.9M |
|
16
Legend Biotech
LEGN
$3.73B
| $24.1M | 3.48% |
+500,000
| New | +$24.5M |
|
17
Sarepta Therapeutics
SRPT
$1.68B
| $22.1M | 3.18% |
160,000
+52,251
| +48% | +$6.78M |
|
18
10x Genomics
TXG
$5.83B
| $19.5M | 2.82% |
+350,000
| New | +$16.3M |
|
19
Inspire Medical Systems
INSP
$1.47B
| $16.4M | 2.36% |
70,000
-10,000
| -13% | -$2.53M |
|
20
Schrodinger
SDGR
$1.14B
| $15.7M | 2.26% |
+595,697
| New | +$14.2M |
|
|
CUTR
21
DELISTED
Cutera, Inc.
CUTR
| $14.2M | 2.04% |
+600,000
| New | +$19.2M |
|
22
908 Devices
MASS
$293M
| $9.03M | 1.3% |
1,050,000
+175,269
| +20% | +$1.56M |
|
|
OLK
23
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| $9.01M | 1.3% |
+400,000
| New | +$8.71M |
|
|
TSVT
24
DELISTED
2seventy bio
TSVT
| $8.86M | 1.28% |
+868,939
| New | +$9.93M |
|
|
SWTX
25
DELISTED
SpringWorks Therapeutics
SWTX
| $8.05M | 1.16% |
+312,664
| New | +$9.14M |
|
Similar funds
8KM
MFG
NP
GGI
WFAL
OBWP
TWM
AGC
Iron Triangle Partners's Q1 2023 Portfolio in Review
As of Q1 2023, Iron Triangle Partners held 38 positions worth $693M, up 24% from $558M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Iron Triangle Partners deployed $108M of net new capital in Q1 2023, opening 12 new positions and adding to 10 existing holdings. Its largest new stake was AbbVie: 320,000 shares worth $51M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Charles River Laboratories, an estimated $15.9M trimmed.
- Iron Triangle Partners's largest Q1 2023 buy was AbbVie: 320,000 shares worth $51M.
- Iron Triangle Partners added most to Sanofi in Q1 2023, an estimated $25.8M increase.
- Iron Triangle Partners's biggest Q1 2023 reduction was Charles River Laboratories, cutting an estimated $15.9M.
- Iron Triangle Partners fully exited Universal Health Services in Q1 2023, selling an estimated $42.3M.
- Iron Triangle Partners's ten largest holdings make up 58% of its $693M portfolio in Q1 2023.
- Iron Triangle Partners opened 12 new positions and closed 11 in Q1 2023.
- Iron Triangle Partners's portfolio value rose 24% quarter-over-quarter to $693M.
Based on Iron Triangle Partners's 13F filing for Q1 2023, filed 15 May 2023.